Apnimed shares surge on bullish BofA initiation

Movers Written by: Angela Harmantas 12:12 Tue 25 Aug 2026 --> Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government. She earned a Bachelor of... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. Apnimed shares surge on bullish BofA initiation Published: 12:12 25 Aug 2026 EDT Shares of Apnimed rose 8% Tuesday after BofA Securities initiated coverage of the company with a Buy rating and a $41 price target. The rating is based on a risk-adjusted discounted cash flow analysis of Oxnimbi (AD109), Apnimed's sole asset and an oral therapy for obstructive sleep apnea (OSA). BofA's thesis centers on three factors: a differentiated mechanism that targets the neuromuscular dysfunction underlying OSA, as opposed to positive airway pressure (PAP) therapy and obesity-directed GLP-1 drugs; positive Phase 3 data showing 34-44% reductions in the apnea-hypopnea index (AHI), which the firm said support a high probability of approval and potentially broad labeling across OSA severity; and a large initial market opportunity among roughly 10.5 million diagnosed but untreated patients. The bank modeled nominal and risk-adjusted peak US sales of approximately $2 billion and $1.7 billion, respectively. Oxnimbi combines aroxybutynin and atomoxetine in a once-daily oral therapy designed to improve upper-airway muscle activity during sleep. If approved, BofA said it would offer a pharmacologic alternative for patients unable or unwilling to use PAP therapy, which remains highly effective but is limited by chronic adherence challenges. Unlike Eli Lilly's Zepbound, which is approved for moderate-to-severe OSA in adults with obesity, Oxnimbi was studied across mild-to-severe OSA and could address much of the population outside the current Zepbound label, according to the note. Both Phase 3 studies met their primary AHI endpoints and showed meaningful reductions in hypoxic burden, the analysts noted. The analysts pointed to two key catalysts ahead: FDA approval and labeling in the first quarter of 2027, which they described as a typical value-step-up event for a single-product biotech, and the Oxnimbi launch itself, where physician feedback supports early uptake given the large addressable patient population and the drug's positioning as an oral option for patients unwilling or unable to use PAP. Continue reading